New and emerging drug molecules against obesity

Journal of Cardiovascular Pharmacology and Therapeutics

Volumn 19, Issue 1, 2014, Pages 65-76

  George, Melvin ^a   Rajaram, Muthukumar ^a   Shanmugam, Elangovan ^a  

^a SRM INSTITUTE OF SCIENCE AND TECHNOLOGY   (India)

Author keywords

emerging drugs; lorcaserin; new drugs; obesity; phentermine topiramate; weight loss

Indexed keywords

AMFEBUTAMONE; AMFEBUTAMONE PLUS NALTREXONE; AMFEBUTAMONE PLUS ZONISAMIDE; AMFEPRAMONE; BELORANIB; CETILISTAT; ERTUGLIFLOZIN; GSK 1521498; GSK 598809; HISTAMINE H3 RECEPTOR; LIRAGLUTIDE; LORCASERIN; MATRIX METALLOPROTEINASE; OXYNTOMODULIN; PF 04620110; PHENDIMETRAZINE; PHENTERMINE PLUS TOPIRAMATE; PLACEBO; RIMONABANT; SIBUTRAMINE; SIRTUIN; TESOFENSINE; TETRAHYDROLIPSTATIN; TTP 435; UNCLASSIFIED DRUG; USISTAPIDE; VASCULOTROPIN; VELNEPERIT; ZONISAMIDE;

ANOREXIA; CLINICAL TRIAL; CONSTIPATION; DIARRHEA; DIZZINESS; DYSPNEA; FOOD AND DRUG ADMINISTRATION; HEADACHE; HUMAN; INSOMNIA; MENTAL DISEASE; METABOLISM; NAUSEA; OBESITY; PARESTHESIA; PRIORITY JOURNAL; REVIEW; TERATOGENICITY; THORAX PAIN; UPPER RESPIRATORY TRACT INFECTION; VOMITING; WEIGHT REDUCTION; XEROSTOMIA;

EMERGING DRUGS; LORCASERIN; NEW DRUGS; OBESITY; PHENTERMINE-TOPIRAMATE; WEIGHT LOSS;

ANIMALS; ANTI-OBESITY AGENTS; APPETITE DEPRESSANTS; CLINICAL TRIALS AS TOPIC; DRUG DESIGN; HUMANS; MOLECULAR TARGETED THERAPY; OBESITY; WORLD HEALTH;

EID: 84890912362     PISSN: 10742484     EISSN: 19404034     Source Type: Journal    
DOI: 10.1177/1074248413501017     Document Type: Review

References (101)

1. WHO. Obesity and Overweight [Internet]; 2013.http://www.who.int/ mediacentre/factsheets/fs311/en/. Accessed May 23, 2013.
2. Wolf AM, Colditz GA. Current estimates of the economic cost of obesity in the United States. Obes Res. 1998 ; 6 (2). 97-106
3. Kumanyika SK, Obarzanek E, Stettler N, et al. Population-based prevention of obesity: the need for comprehensive promotion of healthful eating, physical activity, and energy balance: a scientific statement from American heart association council on epidemiology and prevention, interdisciplinary committee for prevention (formerly the expert panel on population and prevention science). Circulation. 2008 ; 118 (4). 428-464
4. Obesity to Overtake Smoking as Leading Cause of Death [Internet]; 2013. http://www.medscape.com/viewarticle/474966. Accessed May 31, 2013.
5. Lavie CJ, Milani RV, Ventura HO. Obesity and cardiovascular disease: risk factor, paradox, and impact of weight loss. J Am Coll Cardiol. 2009 ; 53 (21). 1925-1932
6. Kremers S, Reubsaet A, Martens M, et al. Systematic prevention of overweight and obesity in adults: a qualitative and quantitative literature analysis. Obes Rev. 2010 ; 11 (5). 371-379
7. Flum DR, Salem L, Elrod JAB, Dellinger EP, Cheadle A, Chan L. Early mortality among medicare beneficiaries undergoing bariatric surgical procedures. JAMA. 2005 ; 294 (15). 1903-1908
8. Wolfe BM, Morton JM. Weighing in on bariatric surgery: procedure use, readmission rates, and mortality. JAMA. 2005 ; 294 (15). 1960-1963
9. Filippatos TD, Derdemezis CS, Gazi IF, Nakou ES, Mikhailidis DP, Elisaf MS. Orlistat-associated adverse effects and drug interactions: a critical review. Drug Saf. 2008 ; 31 (1). 53-65
10. McKay RH. Long-term use of diethylpropion in obesity. Curr Med Res Opin. 1973 ; 1 (8). 489-493
11. Ioannides-Demos LL, Proietto J, Tonkin AM, McNeil JJ. Safety of drug therapies used for weight loss and treatment of obesity. Drug Saf. 2006 ; 29 (4). 277-302
12. Bray GA, Greenway FL. Pharmacological treatment of the overweight patient. Pharmacol Rev. 2007 ; 59 (2). 151-184
13. BELVIQ - 022529lbl.pdf [Internet];2013. http://www.accessdata.fda.gov/ drugsatfda-docs/label/2012/022529lbl.pdf. Accessed May 23, 2013.
14. Thomsen WJ, Grottick AJ, Menzaghi F, et al. Lorcaserin, a novel selective human 5-hydroxytryptamine 2C agonist: in vitro and in vivo pharmacological characterization. J Pharmacol Exp Ther. 2008 ; 325 (2). 577-587
15. Weissman NJ, Tighe JF, Gottdiener JS, Gwynne JT. An assessment of heart-valve abnormalities in obese patients taking dexfenfluramine, sustained-release dexfenfluramine, or placebo. sustained-release dexfenfluramine study group. N Engl J Med. 1998 ; 339 (11). 725-732
16. Sadeque AJM, Usmani KA, Palamar S, Cerny MA, Chen WG. Identification of human UDP-glucuronosyltransferases involved in N-carbamoyl glucuronidation of lorcaserin. Drug Metab Dispos. 2012 ; 40 (4). 772-778
17. Usmani KA, Chen WG, Sadeque AJM. Identification of human cytochrome P450 and flavin-containing monooxygenase enzymes involved in the metabolism of lorcaserin, a novel selective human 5-hydroxytryptamine 2C agonist. Drug Metab Dispos. 2012 ; 40 (4). 761-771
18. Smith SR, Weissman NJ, Anderson CM, et al. Multicenter, placebo-controlled trial of lorcaserin for weight management. N Engl J Med. 2010 ; 363 (3). 245-256
19. Fidler MC, Sanchez M, Raether B, et al. A one-year randomized trial of lorcaserin for weight loss in obese and overweight adults: the BLOSSOM trial. J Clin Endocrinol Metab. 2011 ; 96 (10). 3067-3077
20. O'Neil PM, Smith SR, Weissman NJ, et al. Randomized placebo-controlled clinical trial of lorcaserin for weight loss in type 2 diabetes mellitus: the BLOOM-DM study. Obesity (Silver Spring). 2012 ; 20 (7). 1426-1436
21. Persistent Concerns About Lorcaserin (Lorqess) From FDA Reviewers [Internet]. Forbes;2013. http://www.forbes.com/sites/larryhusten/2012/05/08/ persistent-concerns-about-lorcaserin-lorqe-ss-from-fda-reviewers/. Accessed May 24, 2013.
22. Press Announcements > FDA approves Belviq to treat some overweight or obese adults [Internet];2013. http://www.fda.gov/NewsEvents/Newsroom/ PressAnnouncements/ucm309993.htm. Accessed May 26, 2013.
23. Allison DB, Gadde KM, Garvey WT, et al. Controlled-release phentermine/topiramate in severely obese adults: a randomized controlled trial (EQUIP). Obesity (Silver Spring). 2012 ; 20 (2). 330-342
24. Gadde KM, Allison DB, Ryan DH, et al. Effects of low-dose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER): a randomised, placebo-controlled, phase 3 trial. Lancet. 2011 ; 377 (9774). 1341-1352
25. Garvey WT, Ryan DH, Look M, et al. Two-year sustained weight loss and metabolic benefits with controlled-release phentermine/topiramate in obese and overweight adults (SEQUEL): a randomized, placebo-controlled, phase 3 extension study. Am J Clin Nutr. 2012 ; 95 (2). 297-308
26. Uwaifo G. Cosentino, Conrad A. Phentermine and topiramate for the management of obesity: a review. Drug Des Devel Ther. 2011 ; 7: 267-278
27. Risk Evaluation and Mitigation Strategy (REMS). Qsymia® (phentermine and topiramate extended-release) capsules CIV [Internet];2013. http://www.qsymiarems.com/. Accessed May 31, 2013.
28. Wadden TA, Foreyt JP, Foster GD, et al. Weight loss with naltrexone SR/bupropion SR combination therapy as an adjunct to behavior modification: the COR-BMOD trial. Obesity (Silver Spring). 2011 ; 19 (1). 110-120
29. Greenway FL, Fujioka K, Plodkowski RA, et al. Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2010 ; 376 (9741). 595-605
30. Apovian C, Aronne L, Rubino D, et al. A randomized, phase 3 trial of naltrexone SR/bupropion SR on weight and obesity-related risk factors (COR-II). Obesity (Silver Spring). 2013 ; 21 (5). 935-943
31. Orexigen Therapeutics, Inc. - Contrave [Internet];2013. http://www.orexigen.com/product-candidates/contrave.html. Accessed June 3, 2013.
32. Gadde KM, Yonish GM, Foust MS, Wagner HR. Combination therapy of zonisamide and bupropion for weight reduction in obese women: a preliminary, randomized, open-label study. J Clin Psychiatry. 2007 ; 68 (8). 1226-1229
33. Powell AG, Apovian CM, Aronne LJ. New drug targets for the treatment of obesity. Clin Pharmacol Ther. 2011 ; 90 (1). 40-51
34. Orexigen Therapeutics, Inc. - Press Release [Internet]; 2013. http://ir.orexigen.com/phoenix.zhtml?c=207034&p=irol-newsArticle&id= 1400316. Accessed May 23, 2013.
35. Nielsen A-LH, Larsen TM, Madsbad S, et al. The effect of tesofensine on body weight and body composition in obese subjects - secondary publication [in Danish]. Ugeskr. Laeger. 2009 ; 171 (41). 2974-2977
36. Doggrell SA. Tesofensine - a novel potent weight loss medicine. Evaluation of: Astrup A, Breum L, Jensen TJ, Kroustrup JP, Larsen TM. Effect of tesofensine on bodyweight loss, body composition, and quality of life in obese patients: a randomised, double-blind, placebo-controlled trial. Lancet 2008;372:1906-13. Expert Opin Investig Drugs. 2009 ; 18 (7). 1043-1046
37. Trial irregularities earn Lancet study of potential weight loss drug tesofensine Expression of Concern. Retraction Watch [Internet]; 2013. http://retractionwatch.wordpress.com/2013/04/09/trial-irregularities-earn- lancet-study-of-potential-weight-loss-drug-tesofensine-expression-of-concern/. Accessed May 23, 2013.
38. Yeomans MR, Wright P. Lower pleasantness of palatable foods in nalmefene-treated human volunteers. Appetite. 1991 ; 16 (3). 249-259
39. Yeomans MR, Gray RW. Opioid peptides and the control of human ingestive behaviour. Neurosci Biobehav Rev. 2002 ; 26 (6). 713-728
40. Nathan PJ, O'Neill BV, Napolitano A, Bullmore ET. Neuropsychiatric adverse effects of centrally acting antiobesity drugs. CNS Neurosci Ther. 2011 ; 17 (5). 490-505
41. Nathan PJ, Bush MA, Tao WX, et al. Multiple-dose safety, pharmacokinetics, and pharmacodynamics of the μ-opioid receptor inverse agonist GSK1521498. J Clin Pharmacol. 2012 ; 52 (10). 1456-1467
42. Kopelman P, Bryson A, Hickling R, et al. Cetilistat (ATL-962), a novel lipase inhibitor: a 12-week randomized, placebo-controlled study of weight reduction in obese patients. Int J Obes (Lond). 2007 ; 31 (3). 494-499
43. Kopelman P, Groot G de H, Rissanen A, et al. Weight loss, HbA1c reduction, and tolerability of cetilistat in a randomized, placebo-controlled phase 2 trial in obese diabetics: comparison with orlistat (Xenical). Obesity (Silver Spring). 2010 ; 18 (1). 108-115
44. Valentino MA, Lin JE, Waldman SA. Central and peripheral molecular targets for antiobesity pharmacotherapy. Clin Pharmacol Ther. 2010 ; 87 (6). 652-662
45. Astrup A, Rössner S, Van Gaal L, et al. Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study. Lancet. 2009 ; 374 (9701). 1606-1616
46. Search of: liraglutide AND obesity - List Results - ClinicalTrials.gov [Internet]; 2013. http://www.clinicaltrials.gov/ct2/results?term= liraglutide+AND+obesity&Search=Search. Accessed May 23, 2013.
47. Vilsbøll T, Christensen M, Junker AE, Knop FK, Gluud LL. Effects of glucagon-like peptide-1 receptor agonists on weight loss: systematic review and meta-analyses of randomised controlled trials. BMJ. 2012 ; 344: d7771
48. Maciejewski BS, Laperle JL, Chen D, et al. Pharmacological inhibition to examine the role of DGAT1 in dietary lipid absorption in rodents and humans. Am J Physiol Gastrointest Liver Physiol. 2013 ; 304 (11). G958 - G969
49. Search of: PF-04620110 - List Results - ClinicalTrials.gov [Internet]; 2013. http://www.clinicaltrials.gov/ct2/results?term=PF-04620110&Search= Search. Accessed May 28, 2013.
50. The Science - Our Approach - Zafgen [Internet]; 2013. http://zafgen.com/zafgen/our-approach/the-science. Accessed May 24, 2013.
51. Hughes TE, Kim DD, Marjason J, Proietto J, Whitehead JP, Vath JE Obes (Silver Spring). 2013 :
52. Search of: beloranib - List Results - ClinicalTrials.gov [Internet]; 2013. http://www.clinicaltrials.gov/ct2/results?term=beloranib&Search= Search. Accessed May 24, 2013.
53. Timmers S, Konings E, Bilet L, et al. Calorie restriction-like effects of 30 days of resveratrol supplementation on energy metabolism and metabolic profile in obese humans. Cell Metab. 2011 ; 14 (5). 612-622
54. Brakenhielm E, Cao Y. Angiogenesis in adipose tissue. Methods Mol Biol. 2008 ; 456: 65-81
55. Christiaens V, Lijnen HR. Angiogenesis and development of adipose tissue. Mol Cell Endocrinol. 2010 ; 318 (1-2). 2-9
56. Lijnen HR. Angiogenesis and obesity. Cardiovasc Res. 2008 ; 78 (2). 286-293
57. Silha JV, Krsek M, Sucharda P, Murphy LJ. Angiogenic factors are elevated in overweight and obese individuals. Int J Obes (Lond). 2005 ; 29 (11). 1308-1314
58. npre20116256-1.pdf [Internet];2013. http://precedings.nature.com/ documents/6256/version/1/files/npre20116256-1.pdf. Accessed May 28, 2013.
59. nyhf2-10-hottechnologies-angiolab.pdf [Internet]; 2013. http://www.nyhf.org/docs/nyhf2-10-hottechnologies-angiolab.pdf. Accessed May 28, 2013.
60. Yoon M, Kim M-Y. The anti-angiogenic herbal composition Ob-X from Morus alba, Melissa officinalis, and Artemisia capillaris regulates obesity in genetically obese ob/ob mice. Pharm Biol. 2011 ; 49 (6). 614-619
61. Takeda Submits a New Drug Application for Cetilistat (Development Code: ATL-962) in Japan for the Treatment of Obesity with Complications. Takeda Pharmaceutical Company Limited [Internet];2013. http://www.takeda.com/news/2012/ 20121030-4004.html. Accessed June 1, 2013.
62. Cardiovascular Outcomes Study of Naltrexone SR/Bupropion SR in Overweight and Obese Subjects With Cardiovascular Risk Factors (The Light Study) - Full Text View - ClinicalTrials.gov [Internet]; 2013. http://clinicaltrials.gov/ct2/ show/NCT01601704?term=contrave&rank=3. Accessed June 1, 2013.
63. Orexigen Therapeutics, Inc. - Empatic [Internet]; 2013. http://www.orexigen.com/product-candidates/empatic.html. Accessed June 1, 2013.
64. Effect of Liraglutide on Body Weight in Non-diabetic Obese Subjects or Overweight Subjects With Co-morbidities: SCALETM - Obesity and Pre-diabetes - Full Text View - ClinicalTrials.gov [Internet];2013. http://clinicaltrials.gov/ ct2/show/NCT01272219?term=Liraglutide+AND+obesity&rank=1. Accessed June 1, 2013.
65. Search of: velneperit - List Results - ClinicalTrials.gov [Internet]; 2013. http://clinicaltrials.gov/ct2/results?term=velneperit&Search=Search. Accessed June 1, 2013.
66. Search of: tesofensine - List Results - ClinicalTrials.gov [Internet]; 2013. http://www.clinicaltrials.gov/ct2/results/displayOpt?flds=a&flds= b&flds=f&submit-fld-opt=on&term=tesofensine&show-flds=Y. Accessed June 1, 2013.
67. A Study of the Safety and Effectiveness of JNJ-16269110 (R256918) in Overweight and Obese Patients - Full Text View - ClinicalTrials.gov [Internet]; 2013. http://clinicaltrials.gov/ct2/show/NCT00622765. Accessed June 1, 2013.
68. Safety Study of the Inhibition of Agouti-related Protein (AgRP) for the Management of Obesity and Weight Loss - Full Text View - ClinicalTrials.gov [Internet]; 2013. http://www.clinicaltrials.gov/ct2/show/NCT00779519?term= TTP435&rank=1. Accessed June 3, 2013.
69. Wynne K, Park AJ, Small CJ, et al. Subcutaneous oxyntomodulin reduces body weight in overweight and obese subjects: a double-blind, randomized, controlled trial. Diabetes. 2005 ; 54 (8). 2390-2395
70. Search of: GSK 1521498 - List Results - ClinicalTrials.gov [Internet]; 2013. http://www.clinicaltrials.gov/ct2/results/displayOpt?flds=a&flds= b&flds=f&submit-fld-opt=on&term=GSK+1521498&show-flds=Y. Accessed May 27, 2013.
71. Effects of the D3 Antagonist GSK598809 on Food Reward and Reinforcement - Full Text View - ClinicalTrials.gov [Internet]; 2013. http://www. clinicaltrials.gov/ct2/show/NCT01039454?term=GSK+598809+AND+obesity&rank=1. Accessed June 1, 2013.
72. Search of: PF-04971729 AND obesity - List Results - ClinicalTrials.gov [Internet]; 2013. http://www.clinicaltrials.gov/ct2/results?term=PF- 04971729+AND+obesity&Search=Search. Accessed June 1, 2013.
73. Search of: PF-04620110 AND obesity - List Results - ClinicalTrials.gov [Internet]; 2013. http://www.clinicaltrials.gov/ct2/results?term=PF- 04620110+AND+obesity&Search=Search. Accessed June 1, 2013.
74. Cooke D, Bloom S. The obesity pipeline: current strategies in the development of anti-obesity drugs. Nat Rev Drug Discov. 2006 ; 5 (11). 919-931
75. Greenway FL, Caruso MK. Safety of obesity drugs. Expert Opin Drug Saf. 2005 ; 4 (6). 1083-1095
76. Ioannides-Demos LL, Proietto J, McNeil JJ. Pharmacotherapy for obesity. Drugs. 2005 ; 65 (10). 1391-1418
77. Abenhaim L, Moride Y, Brenot F, et al. Appetite-suppressant drugs and the risk of primary pulmonary hypertension. International primary pulmonary hypertension study group. N Engl J Med. 1996 ; 335 (9). 609-616
78. Jick H, Vasilakis C, Weinrauch LA, Meier CR, Jick SS, Derby LE. A population-based study of appetite-suppressant drugs and the risk of cardiac-valve regurgitation. N Engl J Med. 1998 ; 339 (11). 719-724
79. Sachdev M, Miller WC, Ryan T, Jollis JG. Effect of fenfluramine- derivative diet pills on cardiac valves: a meta-analysis of observational studies. Am Heart J. 2002 ; 144 (6). 1065-1073
80. Glazer G. Long-term pharmacotherapy of obesity 2000: a review of efficacy and safety. Arch Intern Med. 2001 ; 161 (15). 1814-1824
81. Kernan WN, Viscoli CM, Brass LM, et al. Phenylpropanolamine and the risk of hemorrhagic stroke. N Engl J Med. 2000 ; 343 (25). 1826-1832
82. Li Z, Maglione M, Tu W, et al. Meta-analysis: pharmacologic treatment of obesity. Ann Intern Med. 2005 ; 142 (7). 532-546
83. Uretsky S, Messerli FH, Bangalore S, et al. Obesity paradox in patients with hypertension and coronary artery disease. Am J Med. 2007 ; 120 (10). 863-870
84. Wassertheil-Smoller S, Fann C, Allman RM, et al. Relation of low body mass to death and stroke in the systolic hypertension in the elderly program. The SHEP cooperative research group. Arch Intern Med. 2000 ; 160 (4). 494-500
85. Lavie CJ, Alpert MA, Arena R, Mehra MR, Milani RV, Ventura HO. Impact of obesity and the obesity paradox on prevalence and prognosis in heart failure. JACC Heart Fail. 2013 ; 1 (2). 93-102
86. Flegal KM, Kit BK, Orpana H, Graubard BI. Association of all-cause mortality with overweight and obesity using standard body mass index categories: a systematic review and meta-analysis. JAMA. 2013 ; 309 (1). 71-82
87. Fonarow GC, Srikanthan P, Costanzo MR, Cintron GB, Lopatin M. ADHERE Scientific Advisory Committee and Investigators. An obesity paradox in acute heart failure: analysis of body mass index and inhospital mortality for 108,927 patients in the acute decompensated heart failure national registry. Am Heart J. 2007 ; 153 (1). 74-81
88. Artham SM, Lavie CJ, Milani RV, Ventura HO. Value of weight reduction in patients with cardiovascular disease. Curr Treat Options Cardiovasc Med. 2010 ; 12 (1). 21-35
89. Christensen R, Kristensen PK, Bartels EM, Bliddal H, Astrup A. Efficacy and safety of the weight-loss drug rimonabant: a meta-analysis of randomised trials. Lancet. 2007 ; 370 (9600). 1706-1713
90. Mitchell PB, Morris MJ. Depression and anxiety with rimonabant. Lancet. 2007 ; 370 (9600). 1671-1672
91. James WPT, Caterson ID, Coutinho W, et al. Effect of sibutramine on cardiovascular outcomes in overweight and obese subjects. N Engl J Med. 2010 ; 363 (10). 905-917
92. Amylin and Takeda Discontinue Development of Pramlintide/Metreleptin Combination Treatment for Obesity Following Commercial Reassessment of the Program. Takeda Pharmaceutical Company Limited [Internet]; 2013. http://www.takeda.com/news/2011/20110805-3889.html. Accessed June 3, 2013.
93. Proefschrift Edwin Parlevliet 180810-06.pdf [Internet]; 2013. https://openaccess.leidenuniv.nl/bitstream/handle/1887/16080/06.pdf?sequence=9. Accessed May 24, 2013.
94. A Weight Loss Study in Overweight Men and Women - Full Text View - ClinicalTrials.gov [Internet]; 2013. http://www.clinicaltrials.gov/ct2/show/ NCT00993421?term=LY377604&rank=1. Accessed June 3, 2013.
95. Barak N, Greenway FL, Fujioka K, Aronne LJ, Kushner RF. Effect of histaminergic manipulation on weight in obese adults: a randomized placebo controlled trial. Int J Obes (Lond). 2008 ; 32 (10). 1559-1565
96. Ali AH, Yanoff LB, Stern EA, et al. Acute effects of betahistine hydrochloride on food intake and appetite in obese women: a randomized, placebo-controlled trial. Am J Clin Nutr. 2010 ; 92 (6). 1290-1297
97. Aronne LJ, Tonstad S, Moreno M, et al. A clinical trial assessing the safety and efficacy of taranabant, a CB1R inverse agonist, in obese and overweight patients: a high-dose study. Int J Obes (Lond). 2010 ; 34 (5). 919-935
98. Krishna R, Gumbiner B, Stevens C, et al. Potent and selective agonism of the melanocortin receptor 4 with MK-0493 does not induce weight loss in obese human subjects: energy intake predicts lack of weight loss efficacy. Clin Pharmacol Ther. 2009 ; 86 (6). 659-66
99. Heal DJ, Gosden J, Smith SL. Regulatory challenges for new drugs to treat obesity and comorbid metabolic disorders. Br J Clin Pharmacol. 2009 ; 68 (6). 861-874
100. Guideline on Weight Control - Adopted - WC500003264.pdf [Internet]; 2013. http://www.ema.europa.eu/docs/en-GB/document-library/Scientific-guideline/2009/ 09/WC500003264.pdf. Accessed June 3, 2013.
101. Guidance for Industry Developing Products for Weight Management - ucm071612.pdf [Internet];2013. http://www.fda.gov/downloads/Drugs/./Guidances/ ucm071612.pdf. Accessed June 3, 2013.